Toby Maher, MD, PhD

Professor of Clinical Medicine

Image of Toby Maher, MD, PhD
Is this your profile? Click to edit

Education and Training

  • University of Southampton Medical School, UK — BM — 1998 — Medicine
  • Royal College of Physicians, London, UK — FRCP — 2002 — Internal Medicine
  • Imperial College London, London — MSc — 2004 — Respiratory Medicine
  • University College London, London — PhD — 2009 — Medicine

Research Keywords

  • Idiopathic pulmonary fibrosis
  • Interstitial lung disease
  • Connective tissue disease
  • Biomarkers
  • Clinical Trials
  • Sarcoidosis

Publications

  • Fibrosis extent on HRCT: the principal structural imaging biomarker for antifibrotic trials. Eur Respir J. 2026 Oct 29.. View in PubMed
  • Prevalence and mortality of chronic extracellular matrix dysregulated diseases: a nationwide register-based study. Lancet Reg Health Eur. 2027 Jan; 72:101901.. View in PubMed
  • Cross-ancestry evaluation of idiopathic pulmonary fibrosis genetic risk variants. Eur Respir J. 2026 Oct 23.. View in PubMed
  • Protocol and rationale for a randomised, double-blind, placebo-controlled phase 3 trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic pulmonary fibrosis: ALOFT-IPF. BMJ Open Respir Res. 2026 Oct 09; 13(1).. View in PubMed
  • The gut speaks to the lung: Fecal microbiota and survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2026 Oct 01; 212(10):2299-2300.. View in PubMed
  • Gradually, then suddenly: deconvoluting the natural history of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2026 Oct 01; 212(10):2293-2294.. View in PubMed
  • Reply to Sun et al.: Interpreting benefit in ELEVATE-IPF. Am J Respir Crit Care Med. 2026 Sep 01; 212(9):2281-2282.. View in PubMed
  • From Mechanisms to Clinical Practice: Introduction to an AJRCCM Special Section on Interstitial Lung Disease. Am J Respir Crit Care Med. 2026 Aug 17.. View in PubMed
  • Single-cell RNA sequencing reveals aberrant airway epithelial-immune cell cross-talk in pulmonary fibrosis. ERJ Open Res. 2026 Jul; 12(4).. View in PubMed
  • Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial. Am J Respir Crit Care Med. 2026 Aug 01; 212(8):1761-1769.. View in PubMed